Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonazoid CEUS Liver Imaging in Paediatric Patients
2023-505569-95-00Phase 4Authorised
- Sponsor
- GE HealthCare
- Start
- Jul 2025
- Modality
- Acoustic/Optical: Sonoporation, laser photoporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Nanoparticles → Drug Delivery Systems
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of sonazoid in focal liver lesion, sponsored by GE HealthCare. Primary endpoint: Diagnostic performance of Sonazoid-enhanced CEUS for lesion differentiation (vascular phase, blinded read). Planned start Jul 2025; status: authorised.
02
Drugs
sonazoid
03
Conditions
focal liver lesion
Beyond the preview
Go deeper on 2023-505569-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505569-95-00.